RxDoctor Payments Data

Eileen Caquias Gonzalez, MD

Family Medicine · Asheville, NCNPI 1609862010

Payments from drug & device makers

$491in general payments, 2019–2025

Across 10 payments — averaging $49.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$128
  • Sumitomo Pharma America, Inc.$125
  • Sunovion Pharmaceuticals Inc.$78
  • Otsuka America Pharmaceutical, Inc.$73
  • AstraZeneca$49
  • Sun Pharmaceutical Industries Inc.$20
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$491 in reported general payments places this provider in the 55th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$170,065
Medicare patients
590
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,297$407,849
TrulicityDulaglutide179$141,725
IngrezzaValbenazine Tosylate32$107,506
BiktarvyBictegrav/Emtricit/Tenofov Ala20$84,425
XareltoRivaroxaban246$77,154
JardianceEmpagliflozin236$75,450
JanuviaSitagliptin Phosphate195$61,537
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$46,077
RinvoqUpadacitinib17$40,720
NuedextaDextromethorphan Hbr/Quinidine65$38,617
OzempicSemaglutide37$37,677
LinzessLinaclotide63$36,391
DovatoDolutegravir Sodium/Lamivudine11$34,626
TradjentaLinagliptin103$29,318
XifaxanRifaximin33$27,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$128$107,50632 claims
AstraZenecaLokelma, Farxiga, Brilinta$49$43,967107 claims
Acadia Pharmaceuticals IncNuplazid$19$27,48713 claims
Sumitomo Pharma America, Inc.Gemtesa$125$14,92267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →